Head to Head Comparison: Synlogic (SYBX) & Inspyr Therapeutics (NSPX)

Synlogic (NASDAQ:SYBX) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Synlogic and Inspyr Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Synlogic -2,005.43% -37.31% -33.22%
Inspyr Therapeutics N/A N/A N/A

Earnings and Valuation

This table compares Synlogic and Inspyr Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Synlogic $2.52 million 87.96 -$48.44 million ($2.03) -4.30
Inspyr Therapeutics N/A N/A -$11.10 million N/A N/A

Inspyr Therapeutics has lower revenue, but higher earnings than Synlogic.

Volatility & Risk

Synlogic has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Synlogic and Inspyr Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synlogic 0 0 7 0 3.00
Inspyr Therapeutics 0 0 0 0 N/A

Synlogic presently has a consensus price target of $20.67, suggesting a potential upside of 136.73%. Given Synlogic’s higher possible upside, equities analysts clearly believe Synlogic is more favorable than Inspyr Therapeutics.

Institutional & Insider Ownership

81.2% of Synlogic shares are owned by institutional investors. 21.9% of Synlogic shares are owned by company insiders. Comparatively, 0.0% of Inspyr Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Synlogic beats Inspyr Therapeutics on 6 of the 10 factors compared between the two stocks.

About Synlogic

Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

About Inspyr Therapeutics

Inspyr Therapeutics, Inc., an early-stage pharmaceutical company, focuses on the discovery and development of prodrug cancer therapeutics in the United States. It develops cancer therapeutics for the treatment of solid tumors, including brain, liver, prostate, and other cancers. The company's lead drug candidate is mipsagargin, which has completed an open label single arm Phase II clinical trial in patients with advanced hepatocellular carcinoma or liver cancer. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply